Molecular determinant of substrate binding and specificity of cytochrome P450 2J2

被引:8
|
作者
Xu, Liang [1 ]
Chen, Liao Y. [1 ]
机构
[1] Univ Texas San Antonio, Dept Phys & Astron, One UTSA Circle, San Antonio, TX 78249 USA
关键词
MUTATION-INDUCED DYSFUNCTION; HUMAN LIVER-MICROSOMES; ARACHIDONIC-ACID; STRUCTURAL BASIS; CRYSTAL-STRUCTURE; GENERALIZED BORN; PROTEIN MOTIONS; LIGAND-BINDING; FORCE-FIELD; CYP2J2;
D O I
10.1038/s41598-020-79284-0
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Cytochrome P450 2J2 (CYP2J2) is responsible for the epoxidation of endogenous arachidonic acid, and is involved in the metabolism of exogenous drugs. To date, no crystal structure of CYP2J2 is available, and the proposed structural basis for the substrate recognition and specificity in CYP2J2 varies with the structural models developed using different computational protocols. In this study, we developed a new structural model of CYP2J2, and explored its sensitivity to substrate binding by molecular dynamics simulations of the interactions with chemically similar fluorescent probes. Our results showed that the induced-fit binding of these probes led to the preferred active poses ready for the catalysis by CYP2J2. Divergent conformational dynamics of CYP2J2 due to the binding of each probe were observed. However, a stable hydrophobic clamp composed of residues I127, F310, A311, V380, and I487 was identified to restrict any substrate access to the active site of CYP2J2. Molecular docking of a series of compounds including amiodarone, astemizole, danazol, ebastine, ketoconazole, terfenadine, terfenadone, and arachidonic acid to CYP2J2 confirmed the role of those residues in determining substrate binding and specificity of CYP2J2. In addition to the flexibility of CYP2J2, the present work also identified other factors such as electrostatic potential in the vicinity of the active site, and substrate strain energy and property that have implications for the interpretation of CYP2J2 metabolism.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Role of Arginine 117 in Substrate Recognition by Human Cytochrome P450 2J2
    Lafite, Pierre
    Andre, Francois
    Graves, Joan P.
    Zeldin, Darryl C.
    Dansette, Patrick M.
    Mansuy, Daniel
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (07)
  • [2] Danazol Inhibits Cytochrome P450 2J2 Activity in a Substrate-independent Manner
    Lee, Eunyoung
    Wu, Zhexue
    Shon, Jong Cheol
    Liu, Kwang-Hyeon
    DRUG METABOLISM AND DISPOSITION, 2015, 43 (08) : 1250 - 1253
  • [3] Identification of Novel Substrates for Human Cytochrome P450 2J2
    Lee, Caroline A.
    Neul, David
    Clouser-Roche, Andrea
    Dalvie, Deepak
    Wester, Michael R.
    Jiang, Ying
    Jones, J. P., III
    Freiwald, Sascha
    Zientek, Michael
    Totah, Rheem A.
    DRUG METABOLISM AND DISPOSITION, 2010, 38 (02) : 347 - 356
  • [4] Potential of decursin to inhibit the human cytochrome P450 2J2 isoform
    Lee, Boram
    Wu, Zhexue
    Sung, Sang Hyun
    Lee, Taeho
    Song, Kyung-Sik
    Lee, Min Young
    Liu, Kwang-Hyeon
    FOOD AND CHEMICAL TOXICOLOGY, 2014, 70 : 94 - 99
  • [5] Atypical kinetics of cytochrome P450 2J2: Epoxidation of arachidonic acid and reversible inhibition by xenobiotic inhibitors
    Leow, Jacqueline Wen Hui
    Verma, Ravi Kumar
    Lim, Amos Boon Hao
    Fan, Hao
    Chan, Eric Chun Yong
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 164
  • [6] Cytochrome P450 2J2: Potential Role in Drug Metabolism and Cardiotoxicity
    Solanki, Meetal
    Pointon, Amy
    Jones, Barry
    Herbert, Karl
    DRUG METABOLISM AND DISPOSITION, 2018, 46 (08) : 1053 - 1065
  • [7] Cytochrome P450 2J2: distribution, function, regulation, genetic polymorphisms and clinical significance
    Xu, Meijuan
    Ju, Wenzheng
    Hao, Haiping
    Wang, Guangji
    Li, Ping
    DRUG METABOLISM REVIEWS, 2013, 45 (03) : 311 - 352
  • [8] Marmoset cytochrome P450 2J2 mainly expressed in small intestines and livers effectively metabolizes human P450 2J2 probe substrates, astemizole and terfenadine
    Uehara, Shotaro
    Uno, Yasuhiro
    Inoue, Takashi
    Okamoto, Eriko
    Sasaki, Erika
    Yamazaki, Hiroshi
    XENOBIOTICA, 2016, 46 (11) : 977 - 985
  • [9] LKY-047: First Selective Inhibitor of Cytochrome P450 2J2
    Nguyen Minh Phuc
    Wu, Zhexue
    Yuseok, O.
    Lee, Jee-Hyun
    Oh, Sangtaek
    Song, Gyu-Yong
    Liu, Kwang-Hyeon
    DRUG METABOLISM AND DISPOSITION, 2017, 45 (07) : 765 - 769
  • [10] Discovery and Characterization of Novel, Potent, and Selective Cytochrome P450 2J2 Inhibitors
    Ren, Shuang
    Zeng, Juan
    Mei, Ye
    Zhang, John Z. H.
    Yan, S. Frank
    Fei, Jian
    Chen, Li
    DRUG METABOLISM AND DISPOSITION, 2013, 41 (01) : 60 - 71